apoplex medical technologies has specialized in the development of applications to support atrial fibrillation detection. In Germany alone there are around 1 million people with unrecognized and untreated paroxysmal atrial fibrillation. SRA® is used to identify this high-risk group in good time and to enable rapid initiation of therapy.
With our stroke risk analysis SRA®+, the detection of paroxysmal atrial fibrillation (pVHF) and the subsequent cardiological diagnosis of relevant ECG sections are bundled into a holistic prevention offer.
SRA®+ not only detects acute fibrillators, but can also detect an increased probability of paroxysmal atrial fibrillation in fibrillation-free episodes. The fast and accurate results enable a targeted focus on the high-risk group and save personnel and time capacities.
The telecardiological results are available within 24 hours and can be used directly as parameters for therapy decisions. Thus, you have the detection and reporting directly from one source. The diagnosis is performed by a team of cardiologically qualified physicians.
Ensuring the security of sensitive patient data by meeting the highest requirements of MDCG2019-16 and BSI-CS 132. Over 250 hospitals already rely on our service.
Multiple proven performance through numerous international studies. Detection rate is doubled and false positives are 100% eliminated. This relieves the strain on cardiology resources and reduces the patient's length of stay.